HCS Beteiligungsgesellschaft
Taunusanlage 16, Frankfurt am Main, Hessen, 60325, Germany
Overview
HCS Beteiligungsgesellschaft is a German venture capital firm in the management of large and medium sized companies. For more than ten years, they have been involved in companies facing special entrepreneurial challenges, such as initial market entry, internationalization, the establishment of new business areas or corporate succession. The focus of their investment strategy is on companies that distinguish themselves through their technological expertise and their market potential. In the case of companies established on the market, which strive for a new strategic positioning, they usually only consider a majority stake, whereas in the case of young companies that are being set up, they usually take minority stakes. Here, they typically invest between 0.5 and 5.0 million euros. They have extensive experience in leading and advising large medium-sized companies, and have also restructured, reorganized, sold and acquired, including the subsequent group integration. On this basis, they support the companies in their strategic conception and concrete questions for implementation.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- HiperScan
Participated · Equity · Nov 2013
HiperScan GmbH develops scanning grating technology and near-infrared (NIR) spectroscopes used for rapid, cost-efficient identification of substances and mixtures. The company has sold over 400 Apo-Ident NIR spectroscopes to German pharmacies. The report states HiperScan raised €450K in funding (the article also notes the amount "was not disclosed"). The company intends to use the funds to continue technical development of its NIR systems, prioritizing miniaturization, cost optimization and scaling. It also plans to expand operations globally. Led by CEO Dr. Alexander Wolter, HiperScan was founded in 2006 as a spin-off of the Dresdner Fraunhofer Institute for Photonic Microsystems (IPMS).
- Microstim
Participated · Equity · Sep 2013
Microstim is developing a tissue‑maintaining, function‑preserving implantable muscle stimulator intended for muscle‑powered cardiac assistance. The implant continuously monitors stimulation loading of the muscle and counteracts therapy‑threatening overstimulation. The company raised €500K in funding to advance its program. Backers include HCS Beteiligungsgesellschaft, the Technologiefonds MV, High‑TechGruenderfonds and Fides Finanz‑Invest. Microstim intends to use the funds for European CE‑approval and the first clinical application of its system. The company is led by co‑founder and managing director Dr. Peter Klapproth. Microstim GmbH, based in Wismar, Germany, develops a tissue‑maintaining, function‑preserving implantable muscle stimulator for muscle‑powered cardiac assistance. The company’s patented stimulation system permanently monitors stimulation loading of the muscle and counteracts therapy‑threatening overstimulation. Microstim is led by co‑founder and managing director Dr. Klapproth. The product is being developed in collaboration with the Clinic of Cardiac Surgery, Lübeck, at the University Hospital Schleswig‑Holstein. The company has raised €1.5m in funding to advance the program. It intends to use the funds for development, construction and the first clinical application of the stimulator, planned in 2012.
Team
No current team members are available.